Indivior Pharmaceuticals, Inc. (FRA:E7P)

Market Cap	3.47B +224.0%
Revenue (ttm)	1.06B +4.3%
Net Income	178.86M +2,900.0%
EPS	1.40 +3,180.0%
Shares Out	n/a
PE Ratio	19.42
Forward PE	10.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7
Open	28.00
Previous Close	28.20
Day's Range	28.00 - 28.20
52-Week Range	7.75 - 32.80
Beta	n/a
RSI	58.68
Earnings Date	Apr 30, 2026

About Indivior Pharmaceuticals

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 833
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: E7P

Financial Performance

In 2025, Indivior Pharmaceuticals's revenue was $1.24 billion, an increase of 4.29% compared to the previous year's $1.19 billion. Earnings were $210.00 million, an increase of 2900.00%.

Financial numbers in USD